Bowel Function After Minimally Invasive Urogynecologic Surgery

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the effect of a standardized postoperative bowel regimen of over-the-counter medications in subjects undergoing minimally invasive urogynecologic surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Rochester
• Treatments: Bismuth subsalicylate; Psyllium

Criteria

Inclusion Criteria:

• Planning to be admitted to the hospital to undergo minimally-invasive urogynecologic surgery at Strong Memorial Hospital.

Procedures may include:

• robot-assisted laparoscopic sacrocolpopexy

• sacrospinous ligament suspension

• uterosacral ligament suspension/paravaginal defect repair

• colpocleisis

• cystocele repair

Additional procedures may include:

• hysterectomy

• adnexectomy

• culdoplasty

• minimally invasive sling procedure (TVT or TOT)

• periurethral collagen injections

• enterocele repair

Exclusion Criteria:

• Planning to undergo laparotomy.

• Undergoing rectocele or perineocele repair as part of surgery.

• Taking Miralax, laxatives, enemas, or suppositories daily, at the time of enrollment.

• Presence of a colostomy.

• Chronic kidney disease

• Insulin-dependent diabetes mellitus

• Known cardiac disease

• Gastric ulcers

• Difficulty swallowing or esophageal stricture

• Persistent nausea and vomiting

• Signs and symptoms consistent with bowel obstruction